Mirum Pharmaceuticals (MIRM) Gross Profit (2023 - 2026)

Mirum Pharmaceuticals' Gross Profit history runs 4 years deep, the most recent figure standing at $131.1 million for Q1 2026.

• In Q1 2026, Gross Profit rose 48.0% year-over-year to $131.1 million; the TTM figure through Mar 2026 stood at $463.6 million (up 58.53% YoY), while the FY2025 annual figure was $421.1 million, up 64.97% from the prior year.
• Gross Profit was $131.1 million for Q1 2026 at Mirum Pharmaceuticals, up from $120.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $131.1 million in Q1 2026 to a low of $26.6 million in Q1 2023.
• Historically, Gross Profit has averaged $72.8 million across 4 years, with a median of $69.6 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Gross Profit jumped 93.07% in 2024, then surged 48.0% in 2026.
• A 4-year view of Gross Profit shows it stood at $44.5 million in 2023, then jumped by 72.08% to $76.6 million in 2024, then surged by 57.46% to $120.7 million in 2025, then rose by 8.63% to $131.1 million in 2026.
• The last three Gross Profit figures came in at $131.1 million (Q1 2026), $120.7 million (Q4 2025), and $107.5 million (Q3 2025), per Business Quant data.